Medtronic to present new data on its intelligent dosing platforms at the American Diabetes Association 83rd Scientific Sessions

DUBLIN, June 12, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in medical technology, today announced its participation in the upcoming American Diabetes Association's (ADA) 83<sup>rd</sup> Scientific Sessions in San Diego on Jun. 23-26, 2023. During the conference, Medtronic will present new data and clinical outcomes across a broad population of patients from its newly FDA-approved MiniMed™ 780G system with Guardian™ 4 sensor — which began shipping in the U.S. earlier this month — as well as their Extended Infusion Set and InPen™ smart insulin pen.

Medtronic will showcase its most advanced diabetes technology, including next-generation sensors, intelligent dosing systems and automated insulin delivery systems, such as the MiniMed<sup>TM</sup> 780G system, which the <u>recent ADAPT clinical study</u>\* has shown can achieve better outcomes than multiple daily injections (MDI) of insulin with an intermittently scanned CGM (isCGM) alone.

#### **Scientific Presentations**

The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research. Poster presentations will be available to all attendees for viewing throughout the conference.

### MiniMed™ 780G Data Presentations

- "Six Months Experience on Meal Announcement with Three Personalized Presets of Carbohydrates vs. Precise
   Carbohydrate Counting in Adolescents with Type 1 Diabetes Using the MiniMed 780G System" oral presentation (62-OR) by Goran Petrovski, MD, PhD, Sidra Medicine, Doha, Qatar, on Friday, Jun. 23 at 3:00 p.m. PDT
- "12-Month Treatment Satisfaction (TS) and Fear of Hypoglycemia (FoH) Outcomes in the ADAPT study: A Randomized Controlled Trial Comparing an Advanced Hybrid Closed Loop System (AHCL) to Multiple Daily Injections (MDI) with Intermittently Scanned CGM (isCGM)" poster presentation (904-P) by Ohad Cohen, M.D., senior global medical affairs director, Medtronic Diabetes, on Sunday, Jun. 25 at 11:30 a.m. PDT
- "Cost-effectiveness Analysis of MiniMed™ 780G system versus Multiple Daily Injections with Intermittently Scanned CGM (isCGM) A United States Perspective" poster presentation (999-P) by Mallika Kommareddi, MPH, principal health economics and outcomes research specialist, Medtronic Diabetes on Sunday, Jun. 25 at 11:30 a.m. PDT
- "Cost-effectiveness of MiniMed™ 780G Therapy Compared to Multiple Daily Injections (MDI) with Intermittently Scanned Continuous Glucose Monitoring (isCGM) in People with Type 1 Diabetes (T1D): A Singapore Perspective" poster presentation (1009-P) by Daphne Su-Lyn Gardner, MD, senior consultant in endocrinology inSingapore General Hospital on Sunday, Jun. 25 at 11:30 a.m. PDT
- "Robustness of MiniMed™ Advanced Hybrid Closed-Loop (AHCL) Algorithm on a Spectrum of Glycemic Control" poster presentation (927-P) by John Shin, Ph.D., MBA, senior clinical research director, Medtronic Diabetes onSunday, Jun. 25 at 11:30 a.m. PDT
- "Improved Glycemic Control with Less Effort during Real-World MiniMed™ 780G Advanced Hybrid Closed-Loop (AHCL) System Use by Children with T1D" poster presentation (1119-P) by Jen McVean, M.D., pediatric endocrinologist, senior director, medical affairs, Medtronic Diabetes on Monday, Jun. 26 at 11:30 a.m. PDT
- "Higher Time in Range Demonstrated in Children Using Intensive Advanced Hybrid Closed-Loop (AHCL) System Settings" – poster presentation (1120-P) by Jen McVean, M.D., pediatric endocrinologist, senior director, medical affairs, Medtronic Diabetes on Monday, Jun. 26 at 11:30 a.m. PDT

### **Extended Infusion Set (EIS) Presentations**

 "Real-World Clinical Data on the Extended Infusion Set" – poster presentation (910-P) by Tim Kwa, senior product engineer, Medtronic on Sunday, Jun. 25 at 11:30 a.m. PDT

# InPen<sup>™</sup> Presentations

 "Glycemic Impact of Meal-Dosing Behavior in Users of the InPen™ Smart Insulin Pen (SIP) Paired with Continuous Glucose Monitoring (CGM)" – oral presentation (58-OR) by Madison Smith, Ph.D., R.N., CDCES, R&D Clinical Product Manager, Medtronic Diabetes on Friday, Jun 23 at 2:00 p.m. PDT

## **Analyst and Investor Briefing**

Medtronic will host an analyst and investor briefing to highlight initiatives in its Diabetes business or Sunday, Jun. 25 at 1:00 p.m. PDT. Medtronic management, including Geoff Martha, Medtronic chairman and chief executive officer, and Que Dallara, executive vice president and Medtronic Diabetes president, will make a formal presentation immediately followed by answering questions from institutional investors and equity analysts. A live, listen-only webcast will be available and can be accessed by clicking on the Events link at <a href="investorrelations.medtronic.com">investorrelations.medtronic.com</a> on Jun. 25. An archived replay will be available on the same webpage later in the day. This event is not part of the official ADA Scientific Sessions.

## **Medtronic Sponsored Events**

In addition, the following symposia will feature discussions with Medtronic and independent speakers. Details are as follows:

Product Theater: "Global Experience: Success for all on the MiniMed™ 780G system" onSaturday, Jun. 24, 12:30-1:30 p.m. PDT. The event will feature:

Expert	Topic
Jen Sherr, M.D., Ph.D., pediatric endocrinologist	Product overview, including quality of life
at Yale School of Medicine and primary investigator	impact and real-world case study
of the clinical trial of the MiniMed™ 780G system	
Tadej Battelino, M.D., professor, head of the	Ease of use for healthcare professionals
department of pediatric endocrinology, diabetes	
and metabolism at the University Children's Hospital,	
Ljubljana, Slovenia	
Bruno Grassi, Ph.D., assistant professor at the	Evidence across a wide variety of patient types
School of Medicine, Department of Nutrition,	
Diabetes and Metabolism, Pontificia Universidad	
Católica de Chile, Santiago	
Jen McVean, M.D., pediatric endocrinologist,	Clinical evidence overview
senior director, medical affairs, Medtronic Diabetes	

- Exhibit Booth featuring interactive components focused on diabetes technology, clinical outcomes and support offerings for healthcare professionals and patients. In-Booth Presentations will include:
  - "The Brain Behind the Brains of the Minimed™ 780G System: Meet Lou Lintereur and Smartguard™ Technology," on June 24 at 11:30 a.m. PDT by Lou Lintereur, Sr. Distinguished Engineer, Medtronic Diabetes.
  - "The Minimed™ 780G System: Designed for Real Life Including Those Tricky Mealtimes," onJune 24 at 2:00 p.m.
    PDT by Jen McVean, M.D., pediatric endocrinologist, senior director, medical affairs, Medtronic Diabetes.
  - "Closing the Health Disparity Gap through Technology. How InPen™ Smart Insulin Pen Can Help Advance Health Equity," on June 25 at 12:40 p.m. PDT by Nana-Hawa Yayah Jones, M.D., Cincinnati Children's Hospital Medical Center.
  - "Spinal Cord Stimulation: A Therapy for DPN Pain Worthy of Your Referral," on June 25 at 1:10 p.m. PDT by Nalani Hunsaker, PA-C, MCMSc, BC-ADM., Seven Star Endocrinology, Seven Star Medical Group, Menifee, California and Kauai Medical Clinic Hawaii Pacific Health, Lihue, Hawaii

## About the Diabetes Business at Medtronic(www.medtronicdiabetes.com)

Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

<sup>\*</sup>Study design: n=82,  $T1D \ge 2$  years, aged  $\ge 18$  years,  $A1c \ge 8.5\%$ ,  $MDI \ge 2$  years, isCGM  $\ge 3$  months.

## **About Medtronic**

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered inDublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit <a href="https://www.Medtronic.com">www.Medtronic.com</a> and follow <a href="https://www.Medtronic.com">@Medtronic</a> on Twitter and <a href="https://www.Linkedln">Linkedln</a>.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Ryan Janet Cho

Weispfenning

Public Relations Investor Relations

+1-818-403-7028

+1-763-505-4626

SOURCE Medtronic plc

https://news.medtronic.com/2023-06-12-Medtronic-to-present-new-data-on-its-intelligent-dosing-platforms-at-the-American-Diabetes-Association-83rd-Scientific-Sessions